COMPASS Pathways Announces Pivotal Phase 3 Program Design for COMP360 in Treatment-Resistant Depression at Capital Markets Day

  • Proceeds of $1.85 million received from a strategic placement of units at $0.325 per unit, each unit consisting of one common share and one-half common share purchase warrant exercisable at $0.50, for total potential proceeds of $3.27 million.
  • The funding will fuel Optimi’s ongoing commercialization efforts, support new product development and provide the working capital needed to be strategic in the market, with opportunities being explored in Oregon and Alberta.
  • Chip Wilson, founder of lululemon athletica inc., is a society advisor and health and wellness advocate.
  • The private placement brings Chip’s ownership to 9.5% on a fully diluted basis.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a leading GMP producer and advocate for safe supply licensed by Health Canada to produce and distribute natural products , European GMP-Grade Psilocybin and Other Psychedelic Substances, Including MDMA, is pleased to announce that it has closed a non-brokered private placement of 5,692,308 Company Units (each a “Unit”) at the price of $0.325 per Unit (the “Private Placement”) for gross proceeds of $1,850,000 with Wilson Capital, the family office of the Private Equity division of Chip Wilson (“Chip”). The Company intends to use proceeds from the issuance of the Units to support its psychedelic product commercialization efforts, its ongoing psilocybin and MDMA research and clinical trial initiatives, in-house drug development, and its general working capital.

Each Unit consists of one (1) common share of the Company (one ” Ordinary share “) and one-half (1/2) common share purchase warrant (each whole warrant, one ” To guarantee “). Each warrant is exercisable at $0.50 for a period of two (2) years from the date of issue. The common shares and warrants comprising the units and all common shares issued upon exercise of the Warrants are subject to a statutory hold period of four months plus one day from the date of issue in accordance with applicable securities laws.

Optimi welcomes this strategic investment led by the family office of Chip Wilson, founder of lululemon athletica inc., who also sits on Optimi’s advisory board. Mr. Wilson said, “Our participation in the placement demonstrates our belief that the Company can achieve its plan to become a world leader in the development and worldwide distribution of psychedelic products.”

Optimi CEO Bill Ciprick commented, “It is important to demonstrate to both our existing shareholders and the market as a whole that Optimi’s leadership plays an active role in raising smart capital. Looking at a variety of potential financing options to lead this financing round, in addition to ensuring that the terms of the financing were highly competitive, expanding its relationship with Chip through this investment was the preferred scenario. given Chip’s familiarity with the operational business, his ongoing support of Optimi as an advisor and his understanding of the management and background of the Board of Directors and his commitment to achieving his short and long term corporate milestones term. »

The private placement increases the number of common shares of the Company held by the founders, members of the advisory board, directors and officers.

Optimi Co-Founder, Director and Chief Financial Officer, Jacob Safarik, said, “This critical funding puts the Company in the enviable position of being backed by one of Canada’s most trusted wealth management offices. . During this time of market volatility, Optimi has maintained the flexibility to set out on the path to profitability while strengthening its working capital position to pursue important product development and research initiatives that support Optimi’s position as the leading advocate for secure sourcing,” said Safarik. “It is crucial to our continued success that Optimi is ready for opportunities, including the implementation of forensic psychedelic therapy in emerging new markets, such as Oregon and Alberta, and that we have a variety of safe, lab-tested psilocybin and EU-GMP psilocybin MDMA products available to patients around the world as global regulatory markets continue to evolve.”

Strategic Offering Lays Foundation for Company’s Future Expansion Steps, Including Phase I and II Clinical Trials of Psilocybin and MDMA with ATMA Journey Centers, Deployment and Expansion of Mushroom Catalogs Optimi’s functional and psychedelic products, and establishing an operational footprint in Oregon’s regulated psilocybin. market.

Optimi Co-Founder, Director and CMO Dane Stevens said, “This sends the right message at the right time to investors paying close attention to the psychedelic market. When an investor like Chip Wilson offers to increase his position and support the future of Optimi, you find a way to close a deal. Optimi wouldn’t exist without the vision and commitment of JJ and Chip Wilson, the Safarik family, and the shared belief that the work we do today will improve the health of so many in need for many years to come. . Through this strategic raise, we are building trust with shareholders and the operating team, and demonstrating that the company’s founders and management team are committed to Optimi’s long-term success and growth.

The Wilson family recently made headlines for their $100,000,000 donation, the largest in history, to the BC Parks Foundation – as well as the creation of Solve FSHD (a foundation for the search for a cure for facioscapulohumeral muscular dystrophy) with an additional $100 million, in September and March 2022, respectively. These were facilitated by the Wilson 5 Foundation, the family’s private foundation.

FOR SERVICE REQUESTS OR MORE INFORMATION, PLEASE CONTACT:

Michael Kydd
Investor Relations
Email: [email protected]
Telephone: +1 (902) 880 6121

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (ENG: 8BN)

Optimi Health Corp. is a Canadian company licensed by Health Canada to produce and supply EU-GMP grade natural psilocybin and synthetic psychedelic substances and functional mushrooms that focus on the health and wellness markets. Built with the goal of producing scalable psychedelic formulations for transformational human experiences, the company’s goal is to be the trusted and compassionate premier provider of safe medications across the globe. Optimi’s products are manufactured at its two facilities totaling 20,000 square feet in Princeton, BC, making it the largest producer of psilocybin and MDMA in North America.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and beliefs about future events. Any statement that expresses or implies discussions of expectations, beliefs, plans, goals, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as “will result probably”, “are expected to”, “expects”, “will continue”, “is planned”, “anticipates”, “believes”, “estimates”, “intends”, “plans”, ” plans”, “projection”, “strategy”, “goal” and “outlook”) are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results actuals differ materially from those expressed in these forward-looking statements. No assurance can be given that such expectations will prove to be correct and undue reliance should not be placed on any forward-looking statements included in this press release. These statements speak only as of the date of this press release. In particular, and without limitation, this press release contains forward-looking statements relating to the private placement, including with respect to the use of proceeds, the future success of Optimi, the activities proposed to be carried out under the license Company’s Health Canada-approved distributorship and business related to psilocybin, psilocin, other psychedelic substances, some of which are synthetically formulated, and Optimi’s plans, priorities and objectives.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially. of those disclosed or implied by such statements. forward-looking statements. These risks and uncertainties include, but are not limited to, the impact and progression of the COVID-19 pandemic and other factors set forth under the headings “Forward-Looking Statements” and “Risk Factors” in the Company’s Annual Information Form. Company dated January 12, 2022. , and other continuous disclosure documents available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. New factors appear from time to time, and it is not possible for Optimi to predict them all or assess the impact of each of these factors or the extent to which any one factor, or combination of factors, may cause results significantly different from those contained. in any forward-looking statements.

All forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

main logo

Comments are closed.